SCHEMBL4284989

SCHEMBL4284989

CCOC(=O)c1ccc(C(O)c2ccc(OCC)cc2)c(O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.55
CA1 P00915 2/20 0.55
CA2 P00918 2/20 0.55
CA7 P43166 2/20 0.55
CA9 Q16790 2/20 0.55
CA14 Q9ULX7 2/20 0.55
MAPT P10636 4/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
LMNA P02545 2/20 0.47
HSD17B10 Q99714 2/20 0.47
TP53 P04637 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B2 P37059 1/20 0.47
ALDH1A1 P00352 3/20 0.46
GAA P10253 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4282982 0.81 MAPT (0.50) CA12CA1CA2CA7CA9
SCHEMBL8992953 0.79 HSD17B2 (0.56) CA12CA1CA2CA7CA9
SCHEMBL76052 0.77 ALDH1A1 (0.66) CA12CA1CA2CA7CA9
SCHEMBL8993178 0.74 HSD17B2 (0.57) CA12CA1CA2CA7CA9
SCHEMBL28823599 0.74 MAPT (0.60) CA12CA1CA2CA9CA14
SCHEMBL4085075 0.73 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL1990526 0.73 CA12 (0.70) CA12CA1CA2CA7CA9
SCHEMBL7026674 0.72 MAPT (0.46) CA12CA1CA2CA7CA9
SCHEMBL4556519 0.72 LTA4H (0.50) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL39791 0.72 CA12 (1.00) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137499-A1 BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-05-28 US disclosed
EP-2048150-A1 BENZYL PHENYL GLUCOPYRANOSIDE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137499-A1 BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE SLC5A1, SLC5A2, SLC2A1 CA12 2069/4885CA1 2477/4885CA2 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.